Published in Gene Therapy Weekly, August 5th, 2004
CeMines' research and clinical efforts are focusing on molecular mechanisms of the fundamental processes of gene expression-transcription and RNA processing (gene-splicing factors). The company is aggressively pursuing commercialization of a patent-pending platform technology known as CeMines Molecular FingerPrinting focused on development of early-stage diagnostics and targeted therapeutics for cancer and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.